Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Production of virus-specific antiserum corresponding to sequences in the lactate dehydrogenase-elevating virus (LDV) ORF6 protein

H. Takahashi-Omoe, K. Omo, M. Sakaguchi, Y. Kameoka, S. Matsushita, T. Inada

Abstract

The elucidation of the antigenic structure of the envelope proteins of Arteriviridae which includes lactate dehydrogenase-elevating virus (LDV) will provide further understanding of a mechanism of strict host cell specificity. To analyze the linkage between LDV envelope proteins, M/VP-2 and VP-3, which may play an important role in viral infectivity, we generated specific antibody against M/VP-2 that has not been reported in previous studies. A synthetic polypeptide corresponding to the C-terminal region of LDV strain C (LDV-C) ORF6, which encodes M/VP-2, was chemically synthesized and coupled to keyhole limpet hemocyanin (KLH). The peptide was immunogenic in rabbits and induced antibody specific for viral protein. Western blotting and immunofluorescence analysis of virion M/VP-2 in infected macrophages showed that the antibody was able to react specifically with authentic virion protein. The immunoreactive antibody against LDV M/VP-2 described in this study will be useful for further studies of the specific roles of the envelope proteins in arterivirus assembly and infectivity.

Keywords: Arteriviridae; Lactate dehydrogenase-elevating virus; M/VP-2; ORF6; Virus-specific antiserum
Résumé

L’explication de la structure antigénique des protéines d’enveloppe des Arteriviridae, dont le virus de la lacticodehydrogénase (LDV) fait partie, devrait permettre de mieux comprendre le mécanisme de la stricte spécificité des cellules hôtes. Pour analyser les liens entre les protéines d’enveloppe du LDV, à savoir M/VP-2 et VP-3, qui jouent certainement un rôle important dans le pouvoir infectant du virus, nous avons créé un anti-corps spécifique de la M/VP-2 dont il n’a pas encore été fait mention dans les études précédentes. Pour ce faire, nous avons chimiquement synthétisé un polypeptide correspondant à la zone de l’extrémité C d’un virus LDV de souche C (LDV-C), ORF6, codant M/VP-2, et nous l’avons couplé à l’hémocyanine de patelle (KLH). Ce peptide, immunogène chez le lapin, induit un anticorps spécifique à la protéine virale. Le transfert de type western et l’analyse en immunoflorescence de M/VP-2 du virion dans des macrophages infectés ont montré que l’anticorps pouvait réagir de manière spécifique avec une protéine authentique de virion. L’anticorps immunoréactif avec la M/VP-2 du LDV décrit dans cette étude va s’avérer utile dans les études qui vont être conduites sur le rôle spécifique des protéines d’enveloppe dans l’Arteriviridae et dans son pouvoir infectant.

1. Introduction

Attachment of the membrane of enveloped viruses to the plasma membrane of receptive host cells is an essential step for viral entry and infection by enveloped viruses. Analysis of the interaction between these membranes is crucial to describe the process of infection by enveloped viruses, as well as to achieve an understanding of replication and pathogenicity of these viruses.

The Arteriviridae are enveloped positive-stranded RNA viruses comprised of a variety of animal pathogens, including lactate dehydrogenase-elevating virus (LDV), equine arteritis virus (EAV), simian hemorrhagic fever virus (SHFV), and porcine reproductive and respiratory syndrome virus (PRRSV) [1]. The ability to replicate in a variety of cell lines is characteristic of only EAV but not of LDV, SHFV, and PRRSV, which demonstrate strict host cell specificity. Only subpopulations of macrophages from the peritoneum and various tissues of mice support LDV replications [2]. Since no LDV receptors responsible for cell tropism have been identified, the underlying mechanism of the restriction of LDV susceptibility has not yet been elucidated.

LDV possesses two major envelope proteins. The smaller of the two is a 18–19 kDa nonglycosylated protein (M/VP-2; encoded by ORF6) possessing three potential adjacent transmembrane segments close to the N-terminal end, which mimic sequences present in the M protein of coronavirus [3]. The larger protein is a primary envelope glycoprotein (VP-3; encoded by ORF5) that is generally heterogenous in size (25–40 kDa) due to varying amounts of glycosylation [4]. Li et al. [5] have postulated that LDV VP-3 may be the virus attachment protein. Their studies have shown that the neutralization epitope is located in the very short ectodomain of the primary envelope glycoprotein, and that
the epitope is associated with polylactosaminoglycan chains, which may affect the binding of neutralizing antibodies to the LDV virions.

It has been shown that M/VP-2 and VP-3 of LDV are present in virions as heterodimers that are covalently linked by disulfide bond(s), probably located between single cysteine residues in the ectodomains of the two proteins [6]. Since breakage of the disulfide bond(s) in virions resulted in a loss of viral infectivity, the linkage between M/VP-2 and VP-3 seems to be required for host cell entry, perhaps by generating the virion receptor attachment site. Further analysis of the functional properties of VP-3-M/VP-2 heterodimer envelope proteins of LDV will require antibodies directed specifically against each envelope protein. Although much effort has been invested toward the generation of several specific antibodies against LDV VP-3 [7], almost no antibodies that react consistently with virion M/VP-2 have been produced in studies using various immunological methods of analysis such as immunoprecipitation, Western blotting and immunofluorescence. It has been reported that anti-LDV antibodies raised in mice to peptides of ORF6 protein weakly immunoprecipitated in vitro-synthesized ORF6 protein, but even these antibodies did not consistently react with virion M/VP-2 [8]. As a first step to examine the biological and functional properties of LDV M/VP-2, we prepared newly generated specific antibody against LDV ORF6.

2. Materials and methods

2.1. Virus and purification

Purified LDV type C (LDV-C) used in this study were prepared using 8- and 4-week-old SJL/J mice as described previously [9].

2.2. Selection and synthesis of peptide

LDV M/VP-2 possess three potential transmembrane segments near the N-terminal end of which probably functions as an uncleaved signal sequence [8]. Considering the postulated N-terminal ectodomain of ORF6 protein (nine amino acids), which is too short to be an efficient immunogen, a suitable antigenic site for production of specific antibody was predicted as being located in the C-terminal region, which may be located on the cytoplasmic side of the membrane. For this reason, the C-terminal amino acid sequence of the LDV-C ORF6 protein was screened according to Hopp and Woods method [10] for predicting an antigenic region on the basis of hydrophilicity plots. A peptide H2N-CVLGGKKAVSKG-COOH, corresponding to the residue sequence 151−161 in the C-terminal region of LDV-C ORF6 protein, had an extra cysteine-NH2 residue on the N-terminus; this residue was added to allow coupling to the carrier, and was chosen and synthesized by the solid phase method based on Fmoc-chemistry [11] following carrier conjugation to keyhole limpet hemocyanin (KLH) as described in a report by Liu et al. [12].
2.3. Preparation of polyclonal antiserum

Two rabbits, #36 and #37, each received 200 μg of KLH-conjugated peptide emulsified in 1.5 ml complete Freund’s adjuvant (1 × ) and in incomplete Freund’s adjuvant (4 × ) at 3–4-week intervals. Ten weeks later, serum from each rabbit was independently pooled for affinity purification. Each sample of crude antiserum was purified with Protein A sepharose (HiTrap rProtein A, Amersham Biosciences, Buckinghamshire, England).

The purified antibodies #36 and #37 (Ab#36 and Ab#37) were then concentrated and dialyzed.

2.4. ELISA

Rabbit specific IgG to LDV peptide in crude and purified sera were measured by ELISA according to a previously described procedure [13]. In brief, microplates (Nunc Immuno Modules, CovaLink NH, NALGE NUNC International K.K., USA) were activated with N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, HCl (EDC) at room temperature for 2 h, coated with viral peptide or peptide 15-9 corresponding to a major allergen of Japanese cedar pollen [14] (10 μg/ml in phosphate buffered saline (PBS)) overnight at 4 °C. After blocking with 0.1% casein-PBS, pre-immune serum obtained from rabbit #36 and #37 (pre-immune #36 and #37) or anti-peptide serum Ab#36 and #37 diluted with 10% fetal calf serum in PBS were incubated at room temperature (r.t.) for 1 h, and were incubated with peroxidase-conjugated goat anti-rabbit IgG (diluted 1:100) as substrate. After the enzyme reaction was stopped with 4N sulfuric acid, the absorbance at 492 nm was measured with a colorimetric microplate reader (Flow Laboratories, McLean, VA).

2.5. Western blotting

For Western blot analysis, virion protein extracted from LDV-infected SJL/J mouse sera were prepared as described previously [9,15]. The pelleted virus from infected sera was lysed in lysis buffer composed of 50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 0.5% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) sodium dodecyl sulfate (SDS), 1.0% Triton X-100 and Complete (Roche Diagnostics, Mannheim, Germany) as protease inhibitor cocktail. Lysate of LDV virions was separated by SDS–polyacrylamide gels (SDS–PAGE) on 12.5% polyacrylamide gels and was electroblotted onto a polyvinylidene difluoride (PVDF) membrane. The blot was probed with Ab#36 or #37 (diluted 1:100) as mentioned above, then incubated with horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG (diluted 1:10,000), and developed with the enhanced chemiluminescence (ECL) Western blotting analysis system (Amersham Biosciences, Buckinghamshire, England).
2.6. Immunofluorescence analysis

To examine the intracellular localization of LDV M/VP-2 in infected cells, immunofluorescence analysis was performed as described previously [7,16], but with a few modifications. In brief, LDV-C-infected macrophages derived from 4-week-old SJL/J were harvested at 8–10 h post-infection, respectively, and the cells were fixed for 10 min with 2% paraformaldehyde in PBS at 4 °C. After the fixed cells were treated for 10 min in 0.25% Triton X-100 for permeabilization, they were incubated with Ab#36 (diluted 1:100) or pre-immune #36 IgG purified with Protein A sepharose (diluted 1:100) at 4 °C overnight. After a washing with PBS, Alexa Fluor 448 goat anti-rabbit IgG (H+L) (diluted 1:400) (Molecular Probes Co. Ltd, Eugene, USA) were incubated with the cells for 1 h at room temperature. The cells were washed again with PBS, and mounted preparations were observed on LSM510 laser-scanning confocal microscope equipped with an Axiovert-100 M (Carl Zeiss, Oberkochen, Germany).

3. Results

3.1. ELISA

Specificity of the rabbit IgG to LDV ORF6 peptide was assessed by ELISA. As shown in Fig. 1A, both Ab#36 and #37 reacted specifically with LDV ORF6 peptide.
Neither pre-immune #36 nor #37 reacted with LDV peptide. In addition, it was revealed that Ab#36 did not react with a peptide 15-9 against major allergen of Japanese cedar pollen (Fig. 1B). Also Ab#37 did not recognize a peptide 15-9 (data not shown).

3.2. Western blotting

As shown in Fig. 2, Ab#36 clearly reacted with virion M/VP-2, whereas a reaction of Ab#37 was very weak (Fig. 2). The 16 kDa protein, which may represent virion M/VP-2, was detected, although the molecular mass of the detected virion protein was slightly smaller than that of authentic 18–19 kDa virion M/VP-2 reported previously [4].

3.3. Immunofluorescence analysis

Since Ab#36 was clearly capable of reacting with virion M/VP-2 in Western blotting, only Ab#36 was used for the immunofluorescence analysis, which revealed that Ab#36 reacted with virion M/VP-2 in infected macrophages. As shown in Fig. 3C, clear
fluorescence was distributed throughout the cytoplasm of the infected macrophages. The frequency of antigen-positive cells was approximately 5–7%, which was similar to the results obtained from immunostaining using mouse hyperimmune serum by Inada and Mims [17]. It was indicated that no fluorescence was detected in infected macrophages probed with pre-immune #36 IgG (Fig. 3A) and in normal macrophages probed with Ab#36 (Fig. 3B).

4. Discussion

The results of this study suggest that antibodies raised against a peptide corresponding to the C-terminal region of LDV ORF6 protein are able to specifically recognize LDV virion structural envelope protein M/VP-2, as determined by in Western blotting and immunofluorescence analysis. However, in spite of successful production of the specific antibody against virion M/VP-2 achieved in this study, obtaining specific antibodies against M/VP-2 has been very difficult. Other researchers have reported similar difficulties; for example, Coutelier et al. [18] were unable to detect an anti-M/VP-2 response in infected mice, despite a strong response to VP-3. Moreover, in another study, antisera consistently reactive to virion M/VP-2 were not obtained by immunization of animals with bovine serum albumin (BSA)-conjugated synthetic peptides against the C-terminal region of ORF6 protein, which was the same antigenic site chosen in this study [8]. Failure in generating such antibodies may have been due to the immunization methods. It has been reported that KLH and BSA may activate cell mediators such as antigen-presenting cells by different mechanisms due to their respective sizes and their capacities to concentrate in lymphoid centers [19]. Previous study has also shown that peptides coupled with KLH could mimic epitopes present on the native protein structure more accurately than they could those coupled to BSA, with the result that peptides coupled to KLH more efficiently stimulated the immune response [20]. In the same study, it was also reported that plasma raised from peptide coupled to KLH reacted with MHV spike glycoprotein, as shown by Western blotting, whereas the plasma raised from BSA-conjugated peptide reacted only with carrier protein or with spike glycoprotein and carrier protein. A more likely explanation for the difficulty in production of anti-peptide antisera against LDV ORF6 protein may be that linear epitopes do not form a significant part of the antigenic structure, and that conformation-dependent epitopes predominate.

In this report, we have generated antibody only directed to the C-terminal region of the endodomain of LDV M/VP-2 which is not expressed on the virion surface. Although antibodies which react with M/VP-2 on virion surface are necessary for studying virus adsorption to host cell membranes, no such specific antibodies have been available to date. As a next step to generate specific antibodies against M/VP-2, our studies on expression of recombinant M/VP-2 for immunogen are in progress.

In conclusion, we first prepared specific antibody for immunological analysis of LDV envelope protein, M/VP-2. This antibody may prove to be a very useful tool for analysis of the biological and functional properties of the envelope proteins of Arteriviridae.
Acknowledgements

We thank Ms A. Mitsumoto and Ms M. Kaminishi for excellent technical assistance and Mr R. Iritani for his help with the bleedings. Additionally, we are grateful to Dr Y. Harada and Dr Y. Shirakawa for their helpful suggestions.

References

[1] Plagemann PGW. Lactate dehydrogenase-elevating virus and related viruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields Virology. New York: Raven Press; 1996. p. 1105–20.
[2] Ritzi DM, Holth M, Smith MS, Swart WJ, Caffery WA, Plagemann PGW, Stueckemann JA. Replication of lactate dehydrogenase-elevating virus in macrophages. 1. Evidence for cytocidal replication. J Gen Virol 1982;59:245–62.
[3] de Viries AAF, Chinrise ED, Horzinek MC, Rottier PJM. Structural proteins of equine arteritis virus. J Virol 1992;66:6294–303.
[4] Brinton-Darnell M, Plagemann PGW. Structure and chemical–physical characteristics of lactate dehydrogenase-elevating virus and its RNA. J Virol 1979;16:420–33.
[5] Li K, Chen Z, Plagemann PGW. The neutralization epitope of lactate dehydrogenase-elevating virus is located on the short ectodomain of the primary envelope glycoprotein. Virology 1998;242:239–45.
[6] Faaberg KS, Even C, Palmer GA, Plagemann PGW. Disulfide bonds between two envelope proteins of lactate dehydrogenase-elevating virus are essential for viral infectivity. J Virol 1995;69:613–7.
[7] Inada T, Yamazaki S. Replication of lactate dehydrogenase-elevating virus in cells infected with murine leukemia viruses in vitro. J Gen Virol 1991;72:2437–44.
[8] Faaberg KS, Plagemann PGW. The envelope proteins of lactate dehydrogenase-elevating virus and their membrane topography. Virology 1995;212:512–25.
[9] Inada T, Kikuchi H, Yamazaki S. Comparison of the ability of lactate dehydrogenase-elevating virus and its virion RNA to infect murine leukemia virus-infected or -uninfected cell lines. J Virol 1993;67:5698–703.
[10] Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 1981;78:3824–8.
[11] Wellings DA, Atherton E, Standard FMoc protocols. In: Fields GB, editor. Standard FMoc protocols, Solid phase peptide synthesis. Methods Enzymol, 289. New York: Academic Press; 1997. p. 44–67.
[12] Liu FT, Zinnemer M, Hamaoka T, Katz DH. New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunological characterization of such conjugates. Biochemistry 1979;18:690–7.
[13] Sondergaard-Andersen J, Lauritzen E, Lind K, Holm A. Covalently linked peptides for enzyme-linked immunosorbent assay. J Immunol Methods 1990;131:99–104.
[14] Tamura Y, Sasaki R, Inouye S, Kawaguchi J, Serizawa N, Toda M, Takemori T, Sakaguchi M. Identification of a sequential B-cell epitope on major allergen (Cry1) of Japanese cedar (Cryptomeria japonica) pollen in mice. Int Arch Allergy Immunol 2000;123:228–35.
[15] Caffery WA, Chan SPK, Harty JT, Yousefi S, Kowalchyk K, McDonald D, Foreman F, Budweg G, Plagemann PGW. Antibody response of mice to lactate dehydrogenase-elevating virus during infection and immunization with inactivated virus. Virus Res 1986;5:357–75.
[16] Inada T. Replication of lactate dehydrogenase-elevating virus in various species cell lines infected with dual-, ampho- and xenotropic murine leukemia viruses in vitro. Virus Res 1993;27:267–81.
[17] Inada T, Mims CA. Mouse Ia antigens are receptors for lactate dehydrogenase virus. Nature 1984;309:59–61.
[18] Coutelier JP, van Roost E, Lambotte P, van Snick J. The murine antibody response to lactate dehydrogenase-elevating virus. J Gen Virol 1986;67:1099–108.
[19] Wiersma EJ. Enhancement of the antibody response to protein antigens by specific IgG under different experimental conditions. Scand J Immunol 1992;36:193–200.

[20] Daniel C, Lacroix M, Talbot PJ. Mapping of linear antigenic sites on the S glycoprotein of a neurotropic murine coronavirus with synthetic peptides: a combination of nine prediction algorithms fails to identify relevant epitopes and peptide immunogenicity is drastically influenced by the nature of the protein carrier. Virology 1994;202:540–9.